Nathaniel Weygant Selected Research

Doublecortin-Like Kinases

12/2021	DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway.
11/2021	Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity.
12/2020	Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.
1/2020	Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments.
1/2019	Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.
1/2019	Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma.
1/2018	Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
1/2017	Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
1/2016	Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase.
2/2015	DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nathaniel Weygant Research Topics

Disease

28	Neoplasms (Cancer) 01/2022 - 01/2013
6	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 10/2014
6	Pancreatic Neoplasms (Pancreatic Cancer) 06/2020 - 01/2013
5	Inflammation (Inflammations) 01/2021 - 01/2015
5	Adenocarcinoma 06/2020 - 08/2014
5	Carcinogenesis 01/2019 - 01/2013
3	Disease Progression 11/2021 - 01/2018
3	Colonic Neoplasms (Colon Cancer) 01/2020 - 01/2015
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 12/2021 - 01/2016
2	Renal Cell Carcinoma (Grawitz Tumor) 11/2021 - 01/2018
2	Colitis 10/2020 - 01/2015
2	Adenocarcinoma of Lung 06/2020 - 01/2016
2	Stomach Neoplasms (Stomach Cancer) 01/2020 - 01/2016
2	Hepatocellular Carcinoma (Hepatoma) 01/2016 - 11/2015
2	Radiation Injuries (Radiation Sickness) 01/2015 - 03/2014
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Pruritus (Itching) 01/2021
1	Ischemic Stroke 01/2021
1	Brain Injuries (Brain Injury) 01/2021
1	Exanthema (Rash) 01/2021
1	Glioma (Gliomas) 01/2021
1	Ischemia 01/2021
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2021
1	Neoplasm Metastasis (Metastasis) 12/2020
1	Fibrosis (Cirrhosis) 10/2020
1	Angina Pectoris 10/2020
1	Coronary Disease (Coronary Heart Disease) 10/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2020
1	Carcinoma (Carcinomatosis) 01/2016
1	Liver Diseases (Liver Disease) 08/2015
1	Circulating Neoplastic Cells 01/2015
1	Mucositis 01/2015
1	Adenoma (Adenomas) 10/2014
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 08/2014
1	Genomic Instability 01/2013

Drug/Important Bio-Agent (IBA)

14	Doublecortin-Like KinasesIBA 12/2021 - 05/2014
5	MicroRNAs (MicroRNA)IBA 01/2016 - 01/2013
5	Phosphotransferases (Kinase)IBA 01/2016 - 05/2014
3	Immune Checkpoint InhibitorsIBA 11/2021 - 10/2020
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2016
3	RNA (Ribonucleic Acid)IBA 12/2020 - 01/2016
3	Biomarkers (Surrogate Marker)IBA 06/2020 - 01/2016
2	Biological ProductsIBA 01/2022 - 05/2014
2	Monoclonal AntibodiesIBA 12/2020 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 10/2020 - 01/2015
2	ChemokinesIBA 01/2020 - 01/2015
2	CytokinesIBA 01/2020 - 01/2015
2	Messenger RNA (mRNA)IBA 02/2015 - 01/2013
1	Angiotensin IIIBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Neuroprotective AgentsIBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	Long Noncoding RNAIBA 01/2021
1	Chimeric Antigen ReceptorsIBA 12/2020
1	Cisplatin (Platino)FDA LinkGeneric 09/2020
1	Granzymes (Granzyme)IBA 01/2020
1	Protein Isoforms (Isoforms)IBA 01/2019
1	Circulating Tumor DNAIBA 01/2018
1	Small Interfering RNA (siRNA)IBA 01/2017
1	Protein Kinases (Protein Kinase)IBA 01/2017
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2016
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 08/2015
1	Drinking WaterIBA 01/2015
1	Dextran SulfateIBA 01/2015
1	PectinsIBA 01/2015
1	CateninsIBA 01/2015
1	XMD 8-92IBA 08/2014
1	LRRK2-IN1IBA 05/2014
1	villinIBA 03/2014
1	Pravastatin (Pravachol)FDA LinkGeneric 01/2013
1	Antiviral Agents (Antivirals)IBA 01/2013
1	Transcription Factors (Transcription Factor)IBA 01/2013
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2013
1	CholesterolIBA 01/2013

Therapy/Procedure

10	Therapeutics 01/2022 - 01/2016
6	Drug Therapy (Chemotherapy) 01/2022 - 01/2018
3	Immunotherapy 12/2020 - 01/2020
2	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2021 - 10/2020
1	Radiotherapy 01/2015